These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 18539440

  • 1. Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.
    Harada D, Ikeda Y, Nosaka Y, Kobayashi K, Manabe H.
    J Dermatol Sci; 2008 Sep; 51(3):215-9. PubMed ID: 18539440
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R.
    Pulm Pharmacol Ther; 2006 Sep; 19(5):343-52. PubMed ID: 16257550
    [Abstract] [Full Text] [Related]

  • 3. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [Abstract] [Full Text] [Related]

  • 4. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
    Harada D, Takada C, Nosaka Y, Takashima Y, Kobayashi K, Takaba K, Manabe H.
    Int Immunopharmacol; 2009 Jan; 9(1):55-62. PubMed ID: 18854230
    [Abstract] [Full Text] [Related]

  • 5. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D, Tsukumo Y, Takashima Y, Manabe H.
    Eur J Pharmacol; 2006 Feb 17; 532(1-2):128-37. PubMed ID: 16442096
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
    Barone FC, Barton ME, White RF, Legos JJ, Kikkawa H, Shimamura M, Kuratani K, Kinoshita M.
    Pharmacology; 2008 Feb 17; 81(1):11-7. PubMed ID: 17726343
    [Abstract] [Full Text] [Related]

  • 7. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 8. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.
    Herbert C, Hettiaratchi A, Webb DC, Thomas PS, Foster PS, Kumar RK.
    Clin Exp Allergy; 2008 May 08; 38(5):847-56. PubMed ID: 18307529
    [Abstract] [Full Text] [Related]

  • 9. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
    Tatlicioğlu T.
    Tuberk Toraks; 2008 May 08; 56(4):472-84. PubMed ID: 19123088
    [Abstract] [Full Text] [Related]

  • 10. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ, Cortijo J, Morcillo EJ.
    Pharmacol Ther; 2005 Jun 08; 106(3):269-97. PubMed ID: 15922015
    [Abstract] [Full Text] [Related]

  • 11. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
    Kreutzkamp B.
    Med Monatsschr Pharm; 2010 Jul 08; 33(7):236-43. PubMed ID: 20687460
    [Abstract] [Full Text] [Related]

  • 12. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
    Xia XD, Dai YR, Xu ZJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan 08; 27(1):57-9. PubMed ID: 14989829
    [No Abstract] [Full Text] [Related]

  • 13. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA.
    Curr Opin Investig Drugs; 2006 May 08; 7(5):412-7. PubMed ID: 16729716
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ, Giembycz MA, Rennard SI.
    COPD; 2010 Apr 08; 7(2):141-53. PubMed ID: 20397815
    [Abstract] [Full Text] [Related]

  • 15. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB, Gagnon JM.
    Ann Pharmacother; 2006 Jun 08; 40(6):1096-104. PubMed ID: 16735669
    [Abstract] [Full Text] [Related]

  • 16. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE.
    Eur J Pharmacol; 2007 Oct 01; 571(2-3):215-21. PubMed ID: 17610865
    [Abstract] [Full Text] [Related]

  • 17. Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.
    Hoymann HG, Wollin L, Muller M, Korolewitz R, Krug N, Braun A, Beume R.
    Pharmacology; 2009 Oct 01; 83(3):188-95. PubMed ID: 19176983
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N, Palle V.
    Pharmacology; 2009 Oct 01; 83(5):275-86. PubMed ID: 19321962
    [Abstract] [Full Text] [Related]

  • 19. Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
    Heo JY, Cho YS, Cheon HG.
    Pharmazie; 2010 Dec 01; 65(12):906-12. PubMed ID: 21284261
    [Abstract] [Full Text] [Related]

  • 20. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
    McCluskie K, Klein U, Linnevers C, Ji YH, Yang A, Husfeld C, Thomas GR.
    J Pharmacol Exp Ther; 2006 Oct 01; 319(1):468-76. PubMed ID: 16861399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.